Phenotypic analysis of alveolar macrophages and lymphocytes following allergen inhalation by atopic subjects with mild asthma  by Lensmar, C. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 918–925KEYWORD
Alveolar
macrophag
Atopic ast
Allergen c
Phenotype
T cell;
Bronchoalv
lavage
0954-6111/$ - s
doi:10.1016/j.r
$This work w
for Health Care
Correspond
+46 8 5177 0663
E-mail addrPhenotypic analysis of alveolar macrophages and
lymphocytes following allergen inhalation by atopic
subjects with mild asthma$
C. Lensmar, K. Katchar, A. Eklund, J. Grunewald, J. Wahlstro¨mDepartment of Medicine, Division of Respiratory Medicine, Karolinska University Hospital Solna and
Karolinska Institutet, S-171 76 Stockholm, Sweden
Received 22 March 2005; accepted 21 July 2005S
e;
hma;
hallenge;
;
eolar
ee front matter & 2005
med.2005.08.014
as supported by the Sw
Sciences and Allergy R
ing author. Lung Resear
; fax: +46 8 5177 5451.
ess: jan.wahlstrom@ki.Summary
Background: The airway inflammation associated with allergic asthma is initiated
through a complex interaction of antigen-presenting cells (APC) and T lymphocytes
resulting in the release of a cascade of cytokines regulating the progress of the
allergic inflammatory response. In the present study the state of alveolar
macrophage (AM) and T cell activation was investigated following induction of
allergic airway inflammation in individuals with atopic asthma.
Methods: Eleven individuals with mild, atopic asthma received cumulated allergen
inhalations. Before and one day after challenge, bronchoalveolar lavage (BAL) was
performed, and peripheral blood samples obtained. Ten healthy individuals served as
controls. The expression of cell surface markers by BAL fluid AMs and T cells, and by
blood T cells, was investigated by flow cytometry.
Results: All patients developed early asthmatic reactions (EAR) with increased
numbers of eosinophils and mast cells in BAL fluid following allergen challenge. After
allergen challenge, patients had relatively fewer pulmonary CD4+ T cells expressing
CD69 and HLA class II and also relatively fewer pulmonary CD8+ T cells expressing
HLA class II, compared to before challenge. An increased quantitative expression of
CD14 and CD86 was seen within the AM population following allergen challenge.
Conclusion: The results indicate a recruitment of non-activated, immature
macrophages and CD4+ T cells to the airways as well as an altered phenotype
pattern within the AM population following induction of allergic airway inflammation
by allergen inhalation challenge in asthma.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Allergic asthma is associated with an airway
inflammation characterized by a tissue infiltration
of eosinophils, monocytes and lymphocytes. The
allergic inflammatory response is initiated through
a complex interaction of antigen-presenting cells
(APC) and T lymphocytes, resulting in a predomi-
nance of T helper 2 (Th2) cells secreting key
cytokines such as IL-4, IL-5 and IL-13, which
regulate the allergic inflammatory response.1 Al-
veolar macrophages (AMs) may influence the Th1/
Th2 balance in the asthmatic lung, since it has been
shown that under certain conditions distinct sub-
sets of macrophages may skew the cytokine profile
of T cells in either the Th1 or Th2 direction.
Regulatory cytokines, such as IL-10 and TGFb can
also be produced by AMs. The role of AMs in asthma
was recently reviewed in Peters-Golden.2 In the
healthy lung, AMs are generally considered to exert
a downregulatory effect on acquired immune
responses, exemplified by the enhanced antigen
presentation by dendritic cells following AM deple-
tion.3 In a rat model of allergen-induced asthma, in
vivo depletion and adoptive transfer of AMs
between resistant and susceptible strains demon-
strated that AMs suppressed airway hyperrespon-
siveness.4 However, under certain conditions there
may be a failure of AM suppressive mechanisms or
even a switch to a co-stimulatory activity that
could contribute to the airway inflammation,
characterized by T cell activation, Th2 cytokine
secretion and eosinophilia seen in allergic asthma.
AMs of asthmatic individuals express several activa-
tion markers to a higher degree than in healthy
controls (HC).5–7 One study showed that this
expression is further enhanced by allergen chal-
lenge and that levels of several AM markers
correlated with airway sensitivity to metacholine.8
The expression of pro-inflammatory mediators also
differ in AMs from asthmatics compared to con-
trols,9–11 and studies by one group have shown that
AMs from atopic asthmatics have a higher capacity
to induce IL-5 production in CD4+ T cells than do
AMs from atopic individuals without asthma.12,13 A
Th2 stimulatory role for AMs has also been demon-
strated in idiopathic pulmonary fibrosis.14 However,
more studies are clearly needed to better appreci-
ate the role of AMs in allergic asthma.
To investigate the AM/Tcell expression of surface
markers related to activation and co-stimulation
during in vivo allergen exposure, we analyzed by
flow cytometry the phenotypic pattern of cells
recruited by bronchoalveolar lavage (BAL), before
and after birch or grass allergen inhalation by
individuals with mild atopic asthma.Material and methods
Subjects
Eleven patients with mild asthma and radioallergo-
sorbent test (RAST) and skin prick test-verified
allergy to birch pollen (n ¼ 9) or grass pollen
(n ¼ 2) were recruited for the study. All patients
were non-smokers and had previously documented
asthmatic reactions following allergen bronchopro-
vocation. The study population included two males
and nine females, mean age 29 (range 25–32). The
patients were all in a stable phase of disease with
FEV1.0 values ranging from 82.0% to 106.0% of
predicted and received medication with b-agonists
as needed only. Ten healthy non-smoking controls,
five males and five females, mean age 30 (range
19–50) were included in the study. All patients and
subjects had normal chest radiographies and were
without signs of infection at the time of the study;
part of the results from the HC were also used in
another study.15 Written informed consent was
obtained and the study was approved by the local
ethics committee.
Study design
The study was performed outside the pollen season.
Allergen extracts used (Aquagen, ALK, Copenha-
gen, Denmark) were standardized and freeze dried.
Peripheral blood and BAL samples were obtained
2–3 weeks before and 1 day after the allergen
inhalation challenge. All bronchoprovocations were
performed using a dosimeter-controlled jet nebu-
lizer (Spira Elektro 2, Respiratory Care Center,
Hameenlinna, Finland) as previously described.16 In
brief, the allergen challenge started with inhala-
tion of diluent. Provided that FEV1.0 did not change
more than 10%, allergen was inhaled every 15min
with half-log increments of the cumulated dose,
until FEV1.0 dropped 20% or more from the post-
diluent baseline value. Late asthmatic reactions
(LAR) were monitored by measurements of peak
expiratory flow (PEF) rates during 24 h following
allergen challenge. Bronchial provocations with
methacholine were performed in a similar manner
one day before and two days after the allergen
inhalation challenge. The BAL fluid was collected
from HC without prior allergen or methacholine
challenge.
BAL and handling of cells
Bronchoscopy with BAL was performed as pre-
viously described.17 Briefly, BAL fluid was retrieved
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C. Lensmar et al.920by instilling five aliquots of 50ml sterile phoshate
buffered saline (PBS) solution at 37 1C in a middle
lobe bronchus. After each instillation the fluid was
gently aspirated and collected in a siliconized
bottle kept on ice. The BAL fluid was strained
though a double layer of Dacron nets (Millipore,
Bedford, Ireland), centrifuged at 400g for 10min at
4 1C and the cells were resuspended in RPMI 1640
(Sigma Aldrich Co., St. Louis, MO, USA). The BAL
fluid cells were counted in a Bu¨rker chamber and
cell viability (mean ¼ 85%) was determined by
Trypan blue exclusion. For differential cell counts,
cytospins were prepared by cytocentrifugation at
20g for 3min and stained in May–Gru¨nwald Giemsa.
Peripheral blood lymphocytes (PBL) were separated
from heparinized peripheral blood by Ficoll–Hypa-
que (Amersham Pharmacia Biotech, Uppsala, Swe-
den) gradient centrifugation, washed twice and
diluted in RPMI 1640.Immunostaining and flow cytometry
Immunolabeling of AMs was performed using pri-
mary non-conjugated monoclonal antibodies (listed
in Table 1) followed by a secondary phycoerythrine
(RPE)-conjugated antiserum. Antibodies specific for
CD58 and CD83 with isotype-matched controls were
obtained from Serotec (Oxford, UK). CD1a, CD14,
CD16, CD54, CD86 and HLA class I and class II
specific antibodies with isotype-matched controls
were obtained from DAKO (Glostrup, Denmark).
Phenotypic characterization of lymphocytes was
performed using FITC-labeled monoclonal antibo-
dies specific for HLA class II (Dako) and CD69
(Becton Dickinson, Mountain View, CA, USA).Table 1 Description of monoclonal antibodies used
lymphocytes (L).
Monoclonal antibody specificity Major function/
CD1a Dendritic cells
CD14 LPS-receptor, a
CD16 Fc-receptor, act
CD54 Adhesion molec
CD58 Adhesion molec
CD83 Mature antigen
CD86 Co-stimulation
HLA class I Activation
HLA class II Late activation
CD69 Early activation
CD3 T cells
CD4 T cell subset
CD8 T cell subsetMonoclonal RPE-Cy5 conjugated CD4 antibodies,
RPE conjugated CD8 antibodies and FITC conju-
gated CD3 antibodies were obtained from Dako.
Triple staining of cells was performed to determine
the expression of activation markers by CD4+ and
CD8+ cells, respectively, and to assess the percen-
tage of CD3+ cells that expressed CD4 and CD8.
After antiserum incubations and washings, cells
were fixed in PBS with 1% formaldehyde.
The samples were analyzed in a flow cytometer
(FACSCalibur, Becton Dickinson). Lymphocytes and
AMs were identified and gated by forward and side
light scattering properties. In the AM population,
quantitative levels of each antigen, expressed as
mean fluorescence intensity (MFI), were deter-
mined after subtraction of the background fluores-
cence intensity levels. In the lymphocyte
population, the percentages of positively labeled
cells in the CD4+ and CD8+ subsets were deter-
mined. Isotype matched negative control antibo-
dies always stained less than 1% of CD4+ and CD8+
lymphocytes.Statistical analysis
The data are presented as medians with upper and
lower quartile values (P25–P75) unless otherwise
stated. For intraindividual comparisons of data
retrieved before and after allergen challenge,
Wilcoxon’s signed rank test was used. For compar-
isons of lymphocyte subsets in blood and BAL
samples as well as comparisons between patients
and controls the Mann–Whitney non-parametric
test was used.for immunophenotyping of macrophages (M) and
marker of Clone Used for
NA1/34 M
ctivation Tu¨K4 M
ivation DJ130c M
ule 6.5B5 M
ule BRIC-5 M
presenting cells HB15A M
BU63 M
W6/32 M
CR3/43 M/L
L78 L
UCHT1 L
MT310 L
DK25 L
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Alveolar macrophage phenotype in atopic asthma 921Results
Clinical parameters and BAL fluid cell counts
All patients showed early asthmatic reactions (EAR)
with peak drops of FEV1.0 ranging from 21% to 41%
following allergen challenge. Nine subjects devel-
oped LAR. The patients showed a significantly
increased post-challenge airway reactivity to
methacholine, with median PD20 (the dose causing
a 20% fall in FEV1.0) values of 450 mg (150–1210) one
day before and 135 mg (71–330) two days after the
allergen challenge (Po0:01). Cell counts for BAL
fluid retrieved from the patients before and after
allergen challenge as well as from HC are presented
in Table 2. BAL fluid recovery did not differ
between the groups. The patients with asthma
showed significantly elevated baseline numbers of
lymphocytes, eosinophils and mast cells as com-
pared to controls. Following allergen challenge
significantly increased numbers of total cells,
macrophages and eosinophils as well as increased
numbers of mast cells were seen.
AM antigen expression
The AM expression of a number of molecules
involved in antigen presentation and interaction
with Tcells were investigated in BAL fluid retrieved
before and after allergen inhalation challenge of 11
individuals with allergic asthma. A representative
flow cytometry profile of CD14 expression is shown
in Fig. 1. The results, presented as MFI values for
each marker, are summarized in Table 3. Due to a
very restricted amount of cells available from HC,
only markers showing an altered expression follow-
ing allergen exposure were analyzed in the control
material.
The inhalation challenge induced a significantly
increased AM expression of the LPS receptor CD14
and the co-stimulatory molecule CD86 (Table 3),
whereas the baseline expression of the markers did
not differ significantly between asthmatics and HC
(data not shown).
Furthermore, tendencies of an increased expres-
sion of the antigen presentation-related marker
CD1a (P ¼ 0:09) as well as a decreased expression
of HLA class II (P ¼ 0:06) were seen within the AM
population following allergen exposure.
Lymphocyte antigen expression
Immunophenotyping of CD4+ and CD8+ lymphocyte
subsets in peripheral blood and BAL fluid was
performed on the HC as well as before and after
ARTICLE IN PRESS
C. Lensmar et al.922allergen challenge on the asthmatic patients (Table 4).
The lymphocyte subsets were investigated with
regard to expression of the activation markers CD69
(very early activation) and HLA class II (late
activation) and the proportions of CD4+ and CD8+
cells out of CD3+ T cells were analyzed.
A tendency towards an increased proportion of
CD4+ lung T cells as well as a decreased proportion
of CD8+ T cells was seen following allergen
challenge. The BAL fluid CD4/CD8 ratio showed a
non-significant increase from 2.0 to 2.9. No
significant differences were found between pa-
tients and controls.Table 3 Expression of surface markers for activation, a
retrieved from asthmatic patients before and after allerg
Before allergen challenge
CD1a 1.0 (0.3–1.5)
CD14 50.7 (29.0–66.3)
CD16 203.9 (135.3–237.3)
CD54 61.9 (48.7–72.8)
CD58 5.0 (3.5–7.6)
CD83 0.8 (0.2–1.7)
CD86 73.4 (58.9–83.4)
HLA class I 1360 (1057–1710)
HLA class II 1425 (1179–1723)
The mean fluorescence intensity (MFI) values for each marker w
(P25–P75) for the respective MFI values in the group of 11 patien
100
80
60
40
20
0
Co
un
ts
100 101 102 103 104
FL2-H
Neg
CD14
Figure 1 Flow cytometry profiles of one representative
patient before allergen challenge demonstrating CD14
staining (bold) compared to negative control staining
(thin) in the AM population. The x-axis shows the relative
fluorescence on a logarithmic scale and the y-axis shows
the number of events.Asthmatic patients before allergen challenge
were compared with HC with regard to the
expression of activation markers by T cell subsets
in peripheral blood and BAL fluid. There was a
significantly higher frequency of cells expressing
CD69 in the CD4+ subpopulation of peripheral blood
T cells in the patients (Table 4).
Following allergen inhalation challenge there
was a significant reduction in the frequency of
cells expressing CD69 in CD4+ BAL fluid T cells
(Table 4). After allergen challenge there was also
significantly fewer cells expressing HLA class II in
the CD4+ as well as in the CD8+ subsets of BAL fluid
T cells (Table 4). Comparing CD4+ and CD8+ subsets
in BAL fluid with the corresponding subsets in
peripheral blood, in both T cell subsets there were
substantially more cells expressing CD69 and HLA
class II in the lungs of the patients (before and after
allergen challenge) as well as in the lungs of HC,
compared to blood (Table 4).Discussion
The objective of the present study was to investi-
gate the state of alveolar macrophage (AM) and T
cell activation by phenotypic analysis following
allergen inhalation exposure of individuals with
mild atopic asthma. We found that induction of
airway inflammation was associated with a reduced
frequency of pulmonary T cells expressing the
activation marker CD69 and the late activation
marker HLA class II as well as an increased
quantitative expression of CD14 and CD86 within
the AM population, compared to before challenge.
These alterations of the phenotype pattern are
consistent with a recruitment of immature cells to
the airways, but could also, for AMs, be an effect ofdhesion and co-stimulation by alveolar macrophages
en inhalation challenge.
After allergen challenge P
1.6 (1.0–2.3) 0.09
110.6 (73.9–115.4) o0.01
190.7 (109.3–136.4) 0.42
60.6 (53.5–78.8) 0.78
4.1 (2.5–6.4) 0.59
0.8 (0.3–2.1) 0.44
93.4 (60.9–115.1) o0.05
1101 (816–1336) 0.1
1030 (744–1295) 0.06
as determined by FACS analysis. The table depicts median
ts.
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Alveolar macrophage phenotype in atopic asthma 923altered expression induced by allergen exposure
and could be of importance in the regulation of the
allergic airway inflammation. Although we cannot
exclude the possibility that the results may have
been influenced by the methacholine challenge one
day before the allergen challenge, we deem this
unlikely since it has been shown that methacholine
inhalation does not evoke an inflammatory cell
infiltrate in BAL fluid.18
In health the AM is considered to act primarily
immunosuppressive, while certain pulmonary in-
flammatory conditions such as allergic asthma is
associated with a shift of the AM function to a Tcell
stimulatory function.5,12,13 An important factor in T
cell activation is the co-stimulatory signal(s)
delivered by the APC during antigen presentation,
for instance by the CD80/CD86 (B7-1/B7-2) mole-
cules interacting with CD28 on the T cell surface.
Inhibition of this specific co-stimulatory pathway
has been shown to prevent allergen-induced acti-
vation of airway-derived T cells in atopic asthmatic
individuals.19,20 A previous study demonstrated an
induced monocyte expression of CD86 and CD1a
following allergen- or Th2 cytokine stimulation in
vitro, as well as overexpression of CD86 and CD1a
(traditionally seen as a marker of dendritic cells) by
AMs from asthmatics.5 We here show an upregu-
lated AM expression of CD86 one day after allergen
exposure in vivo, a phenotypic shift indicating an
increased accessory cell function within the AM
population. The phenotypic analysis furthermore
showed a post-challenge tendency of an increased
AM expression of the antigen presentation-asso-
ciated marker CD1a.
The increased CD14 expression may be explained
by alterations in AM subsets, following an influx of
blood monocytes.21,22 This is consistent with our
previous demonstration of an altered phenotype,
including an increased expression of CD11b and
CD14, of AM in patients with asthma after repeated
low-dose allergen inhalation challenge.23 Other
investigators have also found that the frequency
of monocytes is increased in asthmatic airways.24,25
However, it is also possible that the CD14 expres-
sion on cells already resident in the lungs has been
upregulated, since it was shown that allergen
exposure leads to increased CD14 expression on
monocytes.26 CD14 has been implicated as a
candidate gene for allergic diseases, since it is
localized in the chromosome 5q31-33 region, which
has been linked to the control of IgE levels, asthma
and bronchial hyperresponsiveness.27 Several poly-
morphisms in the CD14 promoter have been
associated with atopy in various populations.28 An
altered CD14 expression may well lead to a change
in endotoxin response, since CD14 together with
ARTICLE IN PRESS
C. Lensmar et al.924TLR4 is a receptor for lipopolysaccharide (LPS). In
patients with allergic asthma there is increased
expression of CD14 in the airways following allergen
challenge.8 In our low-dose allergen challenge
study AM CD14 expression correlated negatively
with lung function measured as post-challenge
FEV1.
23 A polymorphism in the promoter region of
CD14 has also been shown to be linked to soluble
CD14 levels and total IgE levels.29 One mechanism
behind this could be an altered reactivity to
bacterial products, affecting Th cell differentia-
tion. Furthermore, CD14 has been suggested to
have a role in regulating apoptosis in monocytes,
with increased expression promoting survival.30
These findings suggest several ways in which CD14
expression could be associated with pathogenic
events in allergic asthma.
Comparing the baseline lymphocyte expression of
activation markers in patients and HC, we found a
higher percentage of cells expressing CD69 in CD4+
PBL lymphocytes retrieved from patients before
allergen challenge. A subset of blood CD4+ T cells
thus appears to be activated even in the absence of
symptoms of asthma. A sub-clinical activation of
the immune system is further supported by our
findings of elevated baseline levels of BAL fluid
lymphocytes and eosinophils in the patients (Table
2). Our previous observation of a significantly
altered TCR V gene expression of BAL fluid T cells
derived from individuals with asthma before aller-
gen challenge is also in line with these results.31
The finding that BAL T cells, compared to PBL T
cells, more frequently express CD69 and HLA class II
in patients as well as in controls, is in congruence
with previous reports.32 The significantly decreased
proportion of cells expressing early (CD69) as well
as late (HLA class II) activation markers in the CD4+
BAL fluid T cells after allergen provocation suggests
that the T cells accumulated at this early stage are
non-activated.
Our findings indicate that in vivo allergen
inhalation challenge in subjects with allergic
asthma renders a pulmonary accumulation of
immature monocytes and CD4+ T cells together
with an altered AM phenotypic pattern indicating
the adoption of a T cell stimulatory function, likely
to be of importance for the further development of
the allergic airway inflammation.Acknowledgements
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